Macrogenics Inc
Company Profile
Business description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Contact
9704 Medical Center Drive
RockvilleMD20850
USAT: +1 301 251-5172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
341
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.90 | 5.10 | 0.06% |
| CAC 40 | 7,597.40 | 18.59 | -0.24% |
| DAX 40 | 23,545.56 | 96.02 | -0.41% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,754.62 | 4.37 | -0.05% |
| HKSE | 24,474.67 | 297.60 | 1.23% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,942.07 | 151.51 | 0.39% |
| NZX 50 Index | 12,460.96 | 6.52 | -0.05% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.20 | 3.70 | 0.04% |
| SSE Composite Index | 3,455.97 | 35.41 | 1.04% |